Aroa Biosurgery Ltd · ASX:ARX
Aroa Biosurgery — Shareholder Meeting (July 2021)
8 slides from Aroa Biosurgery's shareholder meeting presentation, Jul 20, 2021
Slide 1: Aroa Biosurgery AGM July 2021 CEO's Report
For personal use only Aroa Biosurgery AGM JULY 2021 CEO’S REPORT Unlocking regenerative healing for everybody
Slide 2: Important Notice and Disclaimer
|2 Important Notice and Disclaimer This report (Report) is dated 20 July 2021 and has been prepared by Aroa Biosurgery Ltd, New Zealand company number 1980577, ARBN 638 867 473 (AROA or the For personal use only Company). Information in this Report The information in this Report is of a general back
Slide 3: AROA at a Glance
|3 AROA at a Glance Well established high-growth soft tissue regeneration company For personal use only NZ$23.1m 68% Gross Margin 4 million+ product sales FY21 on FY21, impacted by lower sales Procedures with constant currency basis and FX AROA’s products 6 patented Regulatory AROA ECM™ product fami
Slide 4: Milestones since listing
|4 Milestones since listing For personal use only Myriad™ Clinical Evidence: Four peer reviewed publications in a wide variety of soft tissue reconstructions Myriad Morcells™: FDA Clearance & commercial launch Symphony™: FDA Clearance & submitted for reimbursement coding Salesforce Expansion: Fully
Slide 5: Catalysts
|5 Catalysts For personal use only Post-COVID AROA Direct Sales TELA Bio® Momentum Vaccinations expected to Fully dedicated improve throughout CY21 field sales team. Myriad expected to Clinical outcomes & cost savings drive growth. driving increasing adoption Product Synergies Clinical Data Compleme
Slide 6: Milestones - FY22
|6 Milestones - FY22 For personal use only H1 FY22 H2 FY22 Myriad Evidence Further clinical publications (H1 & H2 FY22) Endoform Endoform RWD study (H1 FY22) OviTex Bravo Study 24 month outcome reporting (H2 FY22) Symphony Complete Pilot study & initiate RCT (H2 FY22) Symphony Commercial launch (H2
Slide 7: AROA FY22 Outlook
|7 AROA FY22 Outlook For personal use only NZ$30-$33m1 GM product sales FY22 39-53% higher than FY21 improvement • AROA is well placed for FY22 following an improved second half of FY21 and sales transition • Focused on building our US commercial operations over next 24 months to drive revenue growt
Slide 8: Thank you for attending
For personal use only Thank you for attending CONTACTS Simon Hinsley Matt Wright Investor Relations Media m +61 401 809 653 m +61 451 896 420 shinsley@aroabio.com matt@nwrcommunications.com.au 64 Richard Pearse Drive, PO Box 107111, Auckland Airport, Auckland 2150, New Auckland 2022, New Zealand Zea